Literature DB >> 8322231

Experimental studies to assess the potential of photodynamic therapy for the treatment of bronchial carcinomas.

S G Smith1, J Bedwell, A J MacRobert, M H Griffiths, S G Bown, M R Hetzel.   

Abstract

BACKGROUND: Photodynamic therapy (PDT) is a technique for producing localised tissue necrosis with light after prior administration of a photosensitising drug. There is some selectivity of uptake of photosensitisers in malignant tissue, although this is difficult to exploit. Full thickness necrosis in normal and neoplastic colon heals without perforation because of a lack of effect on collagen, making local cure a possibility. The experiments described here aim to establish whether these conclusions are also valid for bronchial tumours.
METHODS: In pharmacokinetic studies normal rats were given 5 mg/kg of the photosensitiser aluminium sulphonated phthalocyanine (A1SPc) intravenously and killed up to one month later. The distribution of A1SPc in the trachea was measured by chemical extraction and fluorescence microscopy. In subsequent experiments sensitised animals were treated with light delivered to the tracheal mucosa through a thin flexible fibre and the resultant lesions were studied for their size, mechanical strength, and healing. A series of resected human bronchial carcinomas were examined histologically for their collagen content.
RESULTS: The tracheal concentration of A1SPc in normal rats was maximum 1-20 hours after administration. Fluorescence microscopy revealed that most was in the perichondrium and submucosal stroma, with little in the cartilage. Light exposure showed necrosis of the soft tissues which healed by regeneration, but no effect on cartilage and no reduction in the mechanical strength of the trachea at any stage. Histological examination of resected human bronchial carcinomas showed more collagen in the tumour areas than would be found in normal regions.
CONCLUSIONS: PDT leads to necrosis of the soft tissues of the normal trachea but there is complete healing by regeneration, no risk of perforation (due to collagen preservation), and no effect on cartilage. Human bronchial carcinomas apparently contain more collagen than normal bronchi which may give protection against perforation following necrosis induced by PDT. PDT may have a role in eradicating small volumes of tumour tissue in situ and could be valuable for treating (1) small carcinomas in patients unfit for resection, (2) tumour remaining after surgical resection, (3) stump recurrences, or (4) to prolong palliation of tumours after debulking with the NdYAG laser.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8322231      PMCID: PMC464496          DOI: 10.1136/thx.48.5.474

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  25 in total

Review 1.  Phthalocyanines as photosensitizers in biological systems and for the photodynamic therapy of tumors.

Authors:  J D Spikes
Journal:  Photochem Photobiol       Date:  1986-06       Impact factor: 3.421

2.  Photoradiation therapy with hematoporphyrin derivative in early and stage 1 lung cancer.

Authors:  Y Hayata; H Kato; C Konaka; R Amemiya; J Ono; I Ogawa; K Kinoshita; H Sakai; H Takahashi
Journal:  Chest       Date:  1984-08       Impact factor: 9.410

3.  Fiberoptic bronchoscopic photoradiation in experimentally induced canine lung cancer.

Authors:  Y Hayata; H Kato; C Konaka; N Hayashi; M Tahara; T Saito; J Ono
Journal:  Cancer       Date:  1983-01-01       Impact factor: 6.860

4.  Hematoporphyrin derivative: quantitative uptake in dimethylhydrazine-induced murine colorectal carcinoma.

Authors:  M V Agrez; R E Wharen; R E Anderson; E R Laws; D M Ilstrup; D A Cortese; R G Shorter; M M Lieber
Journal:  J Surg Oncol       Date:  1983-11       Impact factor: 3.454

5.  Tumor destruction and kinetics of tumor cell death in two experimental mouse tumors following photodynamic therapy.

Authors:  B W Henderson; S M Waldow; T S Mang; W R Potter; P B Malone; T J Dougherty
Journal:  Cancer Res       Date:  1985-02       Impact factor: 12.701

6.  Fluorescence distribution and photodynamic effect of ALA-induced PP IX in the DMH rat colonic tumour model.

Authors:  J Bedwell; A J MacRobert; D Phillips; S G Bown
Journal:  Br J Cancer       Date:  1992-06       Impact factor: 7.640

7.  The detection of phthalocyanine fluorescence in normal rat bladder wall using sensitive digital imaging microscopy.

Authors:  A J Pope; A J MacRobert; D Phillips; S G Bown
Journal:  Br J Cancer       Date:  1991-11       Impact factor: 7.640

8.  Cell uptake, distribution and response to aluminium chloro sulphonated phthalocyanine, a potential anti-tumour photosensitizer.

Authors:  W S Chan; R Svensen; D Phillips; I R Hart
Journal:  Br J Cancer       Date:  1986-02       Impact factor: 7.640

9.  Photodynamic therapy with porphyrin and phthalocyanine sensitisation: quantitative studies in normal rat liver.

Authors:  S G Bown; C J Tralau; P D Smith; D Akdemir; T J Wieman
Journal:  Br J Cancer       Date:  1986-07       Impact factor: 7.640

10.  Photodynamic therapy with phthalocyanine sensitisation: quantitative studies in a transplantable rat fibrosarcoma.

Authors:  C J Tralau; A J MacRobert; P D Coleridge-Smith; H Barr; S G Bown
Journal:  Br J Cancer       Date:  1987-04       Impact factor: 7.640

View more
  3 in total

1.  The role of interventional pulmonary procedures in the management of post-obstructive pneumonia.

Authors:  Ravindra M Mehta; Michael Cutaia
Journal:  Curr Infect Dis Rep       Date:  2006-05       Impact factor: 3.725

2.  Photodynamic therapy on the normal rabbit larynx with phthalocyanine and 5-aminolaevulinic acid induced protoporphyrin IX photosensitisation.

Authors:  D Kleemann; A J MacRobert; T Mentzel; P M Speight; S G Bown
Journal:  Br J Cancer       Date:  1996-07       Impact factor: 7.640

3.  Clinical photodynamic therapy for superficial cancer in the oesophagus and the bronchi: 514 nm compared with 630 nm light irradiation after sensitization with Photofrin II.

Authors:  P Grosjean; G Wagnieres; C Fontolliet; H van den Bergh; P Monnier
Journal:  Br J Cancer       Date:  1998-06       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.